Perimenopause Treatment Options: A Complete Guide to What’s Available

Once a woman recognizes that what she is experiencing is perimenopause, the next question is what to do about it. The answer is rarely simple — there are multiple treatment options, varying levels of evidence supporting each, and significant individual variation in what works for which patient. The conversation is also shaped by decades of public confusion about hormone therapy that has produced both overreaction (the post-WHI era of universal avoidance) and overcorrection (current marketing that sometimes presents HRT as a universal solution).

This article walks through the full landscape of perimenopause treatment options — lifestyle interventions, hormone replacement therapy, supporting peptides, supplements, and other tools — with honest discussion of what the evidence supports, who is a candidate for what, and how to think about constructing a personalized approach. It is the article a woman entering treatment decisions wishes she had read before her first consultation.

The framework for thinking about treatment

Before getting into specific interventions, it is worth establishing the framework for how decisions about perimenopause treatment should be made. The framework has a few key principles.

Treatment is individualized. The right approach for any specific woman depends on her symptoms, severity, age, time since final menstrual period (or stage of perimenopause if still cycling), medical history, family history, risk factors, lifestyle, goals, and preferences. There is no single best perimenopause protocol that applies universally.

Symptoms and risks are addressed simultaneously. Some interventions are primarily about managing acute symptoms — hot flashes, sleep disruption, mood changes. Others are primarily about long-term risk reduction — bone health, cardiovascular health, cognitive function, urogenital health. The best treatment plans typically address both dimensions, often with the same interventions but with awareness of both goals.

Timing matters. The risk-benefit calculus of several interventions, particularly hormone replacement therapy, changes based on when treatment is initiated. The “timing hypothesis” in modern hormone therapy research suggests that benefits are greatest when HRT is started within roughly 10 years of the final menstrual period or before age 60. Other interventions have less timing sensitivity.

Multiple tools work better than single interventions. Perimenopause is multi-dimensional, and treatment that addresses multiple dimensions usually outperforms treatment that addresses only one. A protocol that combines hormone optimization, lifestyle intervention, and targeted symptom-specific treatments typically produces better outcomes than any single intervention alone.

Evaluation is ongoing. The first treatment plan is rarely the long-term plan. Symptoms change as the transition progresses. The body responds to interventions in ways that require adjustment. Comprehensive care involves ongoing monitoring and willingness to refine the protocol over time.

Foundational lifestyle interventions

The lifestyle interventions for perimenopause are not optional add-ons — they are the foundation that the rest of the treatment plan builds on. They are sometimes presented as if they are sufficient on their own, which they generally are not for moderate-to-severe symptoms. But they are necessary even when other interventions are added, because they affect the underlying environment in which the other interventions work.

Sleep. Restoring sleep quality is foundational. The sleep disruption of perimenopause has metabolic, cognitive, mood, and immune consequences that affect every other dimension of well-being. For some women, sleep can be restored largely through addressing the underlying hormonal drivers (hot flashes, night sweats) and other contributors (sleep apnea screening, sleep hygiene). For others, sleep needs direct intervention through hormones, supplements, or sleep-specific peptides.

Resistance training. Structured resistance training two to four times per week addresses several perimenopause concerns simultaneously — muscle preservation (countering sarcopenia), bone density support, metabolic improvement, mood benefits, and body composition. This is the single most effective non-pharmacologic intervention for perimenopausal women and one that many clinical recommendations underemphasize.

Protein intake. Perimenopausal women generally benefit from higher protein intake than they consumed at younger ages — typically 1 to 1.2 grams per pound of target body weight, distributed across the day. Adequate protein supports muscle preservation, satiety, and metabolic health.

Cardiovascular exercise. Regular aerobic activity supports cardiovascular health, mood, sleep, and cognitive function. The specific format matters less than the consistency — three to five sessions per week of moderate-intensity aerobic activity provides the foundational benefit.

Nutrition quality. Whole foods, adequate fiber, sufficient micronutrients, and avoidance of patterns that worsen metabolic health (excessive refined carbohydrates, ultra-processed foods, regular alcohol consumption in significant amounts) all matter. Specific dietary patterns — Mediterranean, lower-carbohydrate, anti-inflammatory — can be appropriate depending on the patient’s specific situation.

Stress and nervous system regulation. Chronic stress and dysregulated nervous system activity worsen most perimenopause symptoms. Practices that support nervous system regulation — meditation, breathwork, yoga, time outdoors, social connection — have measurable effects on cortisol, sleep, and mood. They are not a substitute for clinical intervention when symptoms are significant, but they support whatever else is being done.

For more detail on these foundational pieces in the context of weight management, see our article on perimenopause weight gain.

Hormone replacement therapy: the main treatment category

Hormone replacement therapy is the most evidence-supported intervention for most perimenopause and menopause symptoms, and the most effective intervention for many of them. The modern evidence base supports HRT as both symptomatic treatment and long-term preventive medicine for appropriate candidates.

For comprehensive background on HRT — what it is, the modern evidence, delivery methods, and what evaluation should look like — see our complete HRT guide. For the terminology distinction between MHT and HRT, see our MHT vs HRT article. For the bioidentical question, see our bioidentical vs synthetic article.

For purposes of this treatment guide, the practical considerations include:

Estrogen replacement. Bioidentical estradiol, typically delivered transdermally (patch or gel), is the standard approach for systemic estrogen replacement. Estradiol addresses hot flashes, night sweats, vaginal symptoms, bone density, and many of the cognitive and mood symptoms of perimenopause. The dose is individualized based on symptoms, response, and clinical context.

Progesterone replacement. Oral micronized progesterone, taken at bedtime, is the standard pairing with estrogen for women with intact uterus (to provide endometrial protection) and for symptom benefits more broadly (sleep, anxiety, mood). For women without a uterus, progesterone is still sometimes added for its mood and sleep benefits.

Testosterone for women. Small physiologic doses of testosterone can support libido, energy, mood, body composition, and cognitive function in perimenopausal and postmenopausal women. Testosterone for women is delivered through various methods — typically topical cream, sometimes pellet, occasionally low-dose injection. The doses are much smaller than male TRT, and the goals are different. Many clinics underutilize testosterone for women; it can be a meaningful addition to comprehensive women’s hormone optimization.

Bioidentical preference. Modern practice generally defaults to bioidentical hormones (molecularly identical to human hormones) over older synthetic preparations. FDA-approved bioidenticals are used where available; compounded bioidenticals are used when a specific dose or formulation not available as FDA-approved is clinically appropriate.

Delivery method matters. Transdermal estrogen has more favorable cardiovascular and clotting risk profile than oral estrogen. Pellets, injections, gels, and patches each have advantages and disadvantages — the right choice depends on the patient. For a detailed comparison, see our delivery methods article. Hormone pellets are one option among several.

Who is a candidate. HRT is appropriate for symptomatic women without specific contraindications. Personal or family history of breast cancer, history of significant clotting events, severe liver disease, or other specific conditions may modify or rule out hormone therapy. A thorough evaluation assesses these factors and makes individualized recommendations.

Who should approach with caution or avoid. Women with active or recent breast cancer, severe untreated cardiovascular disease, unexplained vaginal bleeding pending evaluation, active liver disease, or significant clotting disorders generally need to either avoid HRT or use modified approaches with specialist input.

HRT is the largest and most evidence-supported category of perimenopause treatment, and it deserves serious consideration for most symptomatic women. The decision should be made with a clinician who can evaluate the specific picture and discuss both benefits and risks honestly.

Peptide therapy as an adjunct

For some perimenopausal patients, peptide therapy adds value alongside hormone optimization. The peptides used for perimenopause-adjacent concerns are not substitutes for hormone replacement when HRT is what’s actually needed, but they can address specific clinical concerns that hormone therapy alone does not fully reach.

Sleep-supporting peptides. For women with persistent sleep disruption that hormone optimization does not fully resolve, peptides like DSIP can support sleep architecture. The evidence base is primarily from Eastern European clinical literature, and a careful clinician should be transparent about that. For appropriate patients, these can be meaningful additions.

Growth hormone-supporting peptides. Peptides like sermorelin, ipamorelin, and CJC-1295 support endogenous growth hormone release, which can help with recovery, body composition, and sleep quality during the menopause transition. These are appropriate for women with documented decline in growth hormone pulsatility, particularly those dealing with the body composition and recovery challenges of midlife.

Regenerative peptides. For women dealing with the joint pain, soft-tissue issues, or recovery challenges that often accompany perimenopause, BPC-157 and similar regenerative peptides can be useful adjuncts to address specific clinical problems.

Metabolic peptides. For women with significant metabolic resistance that perimenopause has worsened, GLP-1-class peptides like semaglutide and tirzepatide can address the underlying signaling problem. These are typically considered as part of a broader metabolic protocol rather than as standalone perimenopause treatment. Our medical weight loss service and Metabolic Reset program cover this approach in detail.

Cognitive support peptides. Peptides like Selank and Semax have evidence for cognitive support and anxiety reduction, with literature primarily from Eastern European clinical sources. For women whose cognitive and emotional symptoms are not fully addressed by hormone replacement alone, these can be considered as part of an integrated protocol.

Our peptide therapy service integrates these options alongside hormone optimization when the clinical picture warrants.

Non-hormonal medications

For women who cannot or choose not to use hormone replacement therapy, several non-hormonal medications address specific perimenopause symptoms. They are typically less effective than hormones but provide options when hormones are not appropriate.

SSRIs and SNRIs. Low-dose selective serotonin reuptake inhibitors (paroxetine, escitalopram, others) and serotonin-norepinephrine reuptake inhibitors (venlafaxine, others) can reduce hot flashes and address mood symptoms. They are an option for women who cannot use estrogen (history of breast cancer, for example) and for women whose mood symptoms warrant antidepressant treatment regardless of hormonal considerations.

Gabapentin. Originally developed for seizures and neuropathy, gabapentin has documented effects on hot flashes and sleep, particularly at night. It is sometimes used for women who cannot use hormones and have significant nocturnal symptoms.

Clonidine. An older blood pressure medication with documented hot flash benefits. Less commonly used now but still has a role for specific patients.

Fezolinetant. A newer medication specifically approved for vasomotor symptoms of menopause, acting on the neurokinin pathway rather than hormonal pathways. An option for women who cannot use hormones.

Vaginal estrogen. Even for women avoiding systemic hormone therapy, low-dose vaginal estrogen for urogenital symptoms has a favorable safety profile and is appropriate for most patients including those with personal history of certain cancers (with specialist input). The systemic absorption is minimal, and the local benefits for vaginal dryness, painful intercourse, and recurrent UTIs are significant.

Supplements and over-the-counter options

The supplement category for perimenopause is large, varied, and uneven in evidence quality. Some supplements have legitimate evidence; many are marketed without adequate evidence; some are actively counterproductive.

Supplements with reasonable evidence: Magnesium for sleep and muscle cramps. Vitamin D for bone health and broader effects, particularly for women with documented deficiency. Omega-3 fatty acids for cardiovascular and mood support. Vitamin B12 for women with documented deficiency or vegetarian diets. Calcium for bone health, ideally from diet first and supplements only where needed.

Supplements with mixed or limited evidence: Black cohosh for hot flashes (limited evidence, possible liver effects to consider). Phytoestrogens (soy isoflavones, red clover) for hot flashes (modest effects, variable response). Maca for libido and energy (some preliminary evidence). Ashwagandha for stress and cortisol (some evidence for cortisol reduction).

Supplements to be cautious about: Bioidentical hormone supplements sold without prescription (often have inconsistent quality and may not be what they claim). Herbal “hormone balancing” products without specific evidence. Supplements with stimulant effects in women already dealing with anxiety and sleep disruption.

The general principle: supplements have a role, but they are usually not a substitute for addressing significant symptoms with appropriate clinical interventions. Women considering supplements should discuss them with their clinician to avoid interactions and to ensure they are addressing real deficiencies rather than chasing wellness marketing.

Comprehensive lab evaluation

Underneath all the treatment options is the question of how to know what your specific situation requires. A comprehensive laboratory evaluation is the foundation.

For perimenopausal women, this typically includes hormonal markers (FSH, LH, estradiol, progesterone, testosterone, DHEA-S, SHBG, AMH for ovarian reserve assessment), thyroid panel (full thyroid evaluation, not just TSH), metabolic markers (fasting glucose, fasting insulin, HbA1c, comprehensive metabolic panel, lipid panel, hs-CRP), nutrient markers (vitamin D, B12, iron studies, ferritin), and other markers as indicated by the specific clinical picture.

The clinical use of these labs is not to confirm a diagnosis but to inform treatment design. A woman with significantly elevated FSH and low estradiol is in a different stage and likely needs different interventions than a woman with normal FSH and fluctuating estradiol. Insulin resistance affects what metabolic interventions are appropriate. Thyroid issues, if present, often need to be addressed before or alongside other treatments.

Our advanced labs service handles the comprehensive evaluation that good perimenopause treatment requires.

How to build your personalized approach

The treatment approach for any individual woman is built by combining the framework above with her specific picture. Some practical guidance on how to think about it:

Start with foundational lifestyle interventions. Regardless of what medical interventions you may or may not pursue, the foundational pieces — sleep, resistance training, protein, stress regulation — matter. They make every other intervention more effective. They are not optional.

Get comprehensive labs. Without comprehensive labs, you cannot design an appropriate protocol. Insist on more than a single FSH or estradiol measurement. The full picture matters.

Consider HRT seriously if you are a candidate. For most symptomatic women without contraindications, hormone replacement therapy is the most effective single intervention and addresses the underlying driver rather than just managing symptoms. The modern evidence supports HRT as appropriate clinical care, not as a risky last resort.

Add peptide therapy where it fits. For specific clinical concerns — sleep, recovery, metabolic resistance, cognitive support — peptide therapy can add value alongside hormone optimization. It is not a substitute for HRT when HRT is what’s actually needed.

Use non-hormonal medications where appropriate. For women who cannot use hormones, the non-hormonal options provide partial relief and can be combined for additive effect.

Be skeptical of universal solutions. Whether it is a particular supplement, a specific diet, a single medication, or any other “this will fix it” framing, perimenopause is multi-dimensional and rarely responds to a single-vector approach.

Expect to refine over time. The first protocol is the starting point, not the destination. Expect to adjust based on response, on changes in your transition, and on new clinical information as it emerges.

What evaluation should look like in a Houston clinic

A thorough perimenopause evaluation in a clinic that takes the work seriously looks something like this:

A 45 to 60-minute initial consultation that covers detailed symptom history across all the domains discussed in our symptoms article, medical and family history, current medications and supplements, lifestyle assessment, and goals.

Comprehensive baseline labs as described above, ordered before or after the initial consultation depending on workflow.

A follow-up consultation to review lab results and discuss treatment options based on the integrated picture of symptoms and labs.

Individualized treatment plan that may include hormone replacement, peptide therapy where appropriate, lifestyle support, and any other indicated interventions.

Follow-up labs at 6 to 8 weeks after starting therapy or making a significant change.

Quarterly check-ins during the first year, then transition to every six months once stable.

Ongoing willingness to refine the protocol as the transition progresses or as the patient’s situation changes.

This is significantly different from the typical primary care or gynecology workflow, which often allocates 15 minutes for what should be a multi-hour evaluation. The work is not the same as a routine medical visit, and the appropriate care reflects that.

How to think about cost and value

Comprehensive perimenopause care is an investment. Insurance coverage varies widely — some plans cover certain hormone therapies and labs, others cover little to none of what comprehensive perimenopause care involves. For most patients, the cost picture includes some combination of insurance-covered and out-of-pocket components.

The value question is worth thinking about explicitly. Untreated significant perimenopause symptoms have costs of their own — reduced quality of life, reduced work productivity, strain on relationships, and the cumulative effect of years of poor sleep, mood disruption, and physical discomfort. The long-term health risks of unmanaged hormonal decline — bone density loss, cardiovascular changes, urogenital atrophy, cognitive risk — also have costs that show up later.

The patients who treat comprehensive perimenopause care as a worthwhile investment generally find the value. The patients who treat it as a cost to be minimized generally do not get the level of care that produces the best outcomes.

About The Tide

The Tide is a peptide-focused medical clinic in Houston, Texas, located adjacent to the Texas Medical Center. Our women’s hormone health service is built around comprehensive perimenopause and menopause care — detailed evaluation, individualized treatment protocols, integration of hormone replacement and peptide therapy where appropriate, and ongoing monitoring with structured follow-up. We offer hormone replacement therapy, bioidentical hormones, hormone pellets, peptide therapy, and supporting interventions based on what each patient actually needs. Every patient begins with comprehensive baseline labs and a 45-minute physician consultation. For deeper reading, see our clinical standards and programs.